# Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease

Study · id `cardio:ct-nct02294994` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02294994](<https://clinicaltrials.gov/study/NCT02294994>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02294994

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1000 participants.

## Technical summary

Registry record NCT02294994. Randomized; no masking; primary purpose treatment. Start 2014-11 (registry gives no type); primary completion 2016-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1000 participants (planned count; ClinicalTrials.gov record NCT02294994, source copy `cardio:ctgov-nct02294994-2014-12-02`, retrieved 2026-10-26)
- Start date: 2014-11 (registry gives no type) (ClinicalTrials.gov record NCT02294994, source copy `cardio:ctgov-nct02294994-2014-12-02`, retrieved 2026-10-26)
- Primary completion: 2016-12 (anticipated) (ClinicalTrials.gov record NCT02294994, source copy `cardio:ctgov-nct02294994-2014-12-02`, retrieved 2026-10-26)
- Completion: 2016-12 (anticipated) (ClinicalTrials.gov record NCT02294994, source copy `cardio:ctgov-nct02294994-2014-12-02`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02294994, source copy `cardio:ctgov-nct02294994-2014-12-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02294994-2014-12-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease
- Condition: Coronary Artery Disease
- Intervention (Drug): tirofiban
- Lead sponsor: Second Hospital of Jilin University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Second Hospital of Jilin University (`cardio:org-second-hospital-of-jilin-university`)

## Provenance

Content hash: b8fda25e981c504a97f795a0aa580be2c3d577919436e1d47ed718d3ad3c25e9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
